21Country Profiles

Total Page:16

File Type:pdf, Size:1020Kb

21Country Profiles 21 COUNTRY PROFILES An Introduction to Local Pharmaceutical Production Opportunities in Africa TABLE OF CONTENTS: Foreword from UNAIDS 01 02 Foreword from CCCMHPIE Acknowledgements 03 Introduction to Country Profiles 04 Country Profile 1: ALGERIA 11 Country Profile 2: ANGOLA 14 Country Profile 3: CÔTE D’IVOIRE 17 Country Profile 4: EGYPT 20 Country Profile 5: ETHIOPIA 23 Country Profile 6: GABON 26 Country Profile 7: GHANA 29 Country Profile 8: KENYA 32 Country Profile 9: MADAGASCAR 35 Country Profile 10: MALAWI 38 Country Profile 11: MALI 41 Country Profile 12: MAURITIOUS 44 Country Profile 13: MOZAMBIQUE 47 Country Profile 14: NIGERIA 50 Country Profile 15: RWANDA 53 Country Profile 16: SENEGAL 56 Country Profile 17: SOUTH AFRICA 59 Country Profile 18: TANZANIA 62 Country Profile 19: UGANDA 65 Country Profile 20: ZAMBIA 68 Country Profile 21: ZIMBABWE 71 Bibliography 74 FOREWORD FROM UNAIDS A healthy population is essential for prosperity. also strongly believe that local production of This is a now accepted principle of development, medicines and other health products in Africa reflected in the UN Sustainable Development is an attractive proposition - it is estimated Goals agreed in 2015, and in particular SDG3 that the African pharmaceutical sector holds for good health and wellbeing. The principle is a US $45 billion market opportunity by 2020. also reflected in the African continent’s vision Local pharmaceutical manufacturing in African for itself – Agenda 2063, also published in 2015 countries presents an opportunity to save lives by the African Union, and in collective actions while creating jobs and improving the local since 2015 by African countries to strengthen economy. their systems – for instance by their unanimous adoption of a treaty in May 2018 to set up However, our work with international partners an African Medicine Agency (AMA). Indeed, has revealed that there remains a huge lack health is a priority for most African country of information and misunderstanding about development plans for good reason. The African African countries, their needs, their status continent has approximately 15 percent of the and opportunities. This is particularly acute in global population and a disproportionately high China where language barriers and very recent disease burden. It is the continent where over 70 economic development hinders understanding percent of the world’s HIV cases and 90 percent of global markets. of deaths due to malaria occur. I appreciate that our partners here in China – At the same time, many African countries are the China Chamber of Commerce for Import highly dependent on imported pharmaceutical and Export of Medicines and Health Products and medical products. It is estimated that more (CCCMHPIE), and the whole of UNAIDS than 80 percent of Anti-Retroviral drugs (ARVs) has supported this effort to provide a simple, used on the continent are imported from outside, consistent set of information for Chinese and with 70 percent of all pharmaceutical and other companies considering local production medical products market being served by foreign in African countries. With this effort, we hope imports. Where there is local manufacturing, it they will all begin to realise the openness and mainly involves the production of non-complex, willingness of African governments to bring in high volume essential products, such as basic foreign investors into this sector, create joint analgesics, simple antibiotics, anti-malarial partnerships, and inspire as many companies drugs and vitamins. This is an unsustainable as possible to set a vision for how they can situation for two reasons. Imported products contribute to saving lives on the continent, in a can be subject to mark-ups, while jobs are sustainable yet profitable manner. urgently needed on the continent, which local manufacturing could provide for. This is why UNAIDS is so focused on encouraging global pharmaceutical manufacturers – including from China - to set up in African countries. This is based on the strong conviction (also articulated in the African Union Roadmap on Shared Responsibility and Global Solidarity, endorsed by Heads of States in 2012) that access to affordable, quality medication is integral to Ms Amakobe Sande ending AIDS (and other major diseases) and UNAIDS Country Director and achieving Universal Health Coverage. We Representative to the People’s Republic of China 1 FOREWORD FROM CCCMHPIE China accounts for 20% of the world’s population, international organizations and other stake and the healthcare sector is a crucial contributor holders to set the bridge between China and to China’s development. China has strong supply Africa and let more Chinese companies learn side capacity, which attracts foreign companies more about African markets to support their as the second largest market of the world. There business strategy in the long term. are an estimated more than 5,000 domestic pharmaceutical manufacturers. And the market In 2016, CCCMHPIE, the Joint United Nations is continuing to grow and strengthen, to provide Programme on HIV/AIDS (UNAIDS) China universal health insurance and give individuals office and the Bill & Melinda Gates Foundation greater access to products and services. At jointly launched the China-Africa Medical and the same time, we are keen to collaborate Health Cooperation Platform Project (www. internationally to establish and promote healthcac.com), establishing an online database international standards as well as support other to share information about capacity of Chinese countries to address their health challenges. So companies and the market demand of African far, 45 APIs, 24 preparations, 4 vaccines, 3 IVDs countries, organizing regular events and and 2 vector control products have passed the releasing various reports. We hope that this new World Health Organization Pre-Qualification to market profile of 21 African countries, especially enter global pharmaceutical markets. Hundreds the Chinese version, can help Chinese companies of products have been registered successfully in (as well as others from other countries) to go into USFDA, European and the emerging counties and invest in local African manufacturing. authorities. We appreciate UNAIDS’s support for China- As an emerging market for China, the Africa Africa cooperation. We will use these profiles continent is key to our efforts. Health has in our efforts to promote collaboration, and been a long-standing key part of China- Africa look forward to working with UNAIDS and cooperation, initially in the 1960s through other international organizations to continue to medical aid and more recently through support further access to medicines in Africa. exports of relevant drugs to African countries. In December 2015, President Xi Jinping announced the China-Africa Ten Collaboration Plan at the Johannesburg Summit of Forum on China-Africa Cooperation, and for the first time explicitly encouraged the local production of pharmaceuticals in Africa to promote access to medicines, through factory building and other direct investment. In September 2018, the Eight Major Initiatives of the FOCAC Beijing meeting emphasis more on actions follow up in health cooperation. Supported by China’s Ministry of Commerce, CCCMHPIE has focused its efforts and facilitated Chinese companies’ performance in Africa. So far, enterprises such as Humanwell Healthcare, Guilin Pharmaceutical, Shanghai Pharmaceuticals, Sansheng, Yorkool, Tasly and other enterprises have built factories or branches Zhou Hui in Mali, Ethiopia, Uganda and elsewhere. President, China Chamber of Commerce CCCMHPIE is ready to work with the relevant for Import and Export of Chinese Medicines and Health Products 2 ACKNOWLEDGEMENTS UNAIDS China Office and CCCMPHIE would Gabon: Export Promotion Agency Gabon like to take this opportunity to acknowledge all parties who contributed to the development and Ghana: Senior Member of the Pharmaceuticals finalization of these 21 Country Profiles. Manufacturers Association We would like to acknowledge and thank Madagascar: Senior Official from the Ministry of a number African Embassies to China, Public Health who collaborated with us to verify the data presented in the Country Profiles, in particular Mauritius: Private sector representative and the Embassies of Angola, Egypt, Ethiopia, Senior Official pharmaceutical sector, Ministry Madagascar, Malawi, Rwanda, Senegal, South of Health Africa, Tanzania, Uganda and Zambia. Malawi: Chinese manufacturer At country level, we wish to sincerely Nigeria: Representative, private pharmaceutical acknowledge the support and input of the manufacturer UNAIDS Offices in Algeria, Cote D’Ivoire, Kenya, Madagascar, Mali, Mauritius, Zambia: Zambian Medicine Regulatory Mozambique, Nigeria and Zimbabwe who Authority and Zambia Development Agency worked with respective governments to also validate the contents of the report. The COMESA Secretariat Regional Teams in Johannesburg, Dakar and Cairo and well as colleagues in UNAIDS Last but not least, we would like to extend our Headquarters also provided valuable technical sincere thanks to Development Reimagined, an input. independent consulting firm based in China, for the huge undertaking of putting together, We are also indebted and grateful to the completing, designing and translating this following decision-makers, experts and report and supporting the partnership between resource persons who also contributed to the UNAIDS China office and CCCMPHIE is content and verification of data in
Recommended publications
  • The UAE Healthcare Sector
    The U.S.-U.A.E. Business Council is the premier business organization dedicated to advancing bilateral commercial relations. By leveraging its extensive networks in the U.S. and in the region, the U.S.-U.A.E. Business Council provides unparalleled access to senior decision makers in business and government with the aim of deepening bilateral trade and investment. U.S.-U.A.E. Business Council 505 Ninth Street, NW Suite 6010 Washington D.C. +202.863.7285 [email protected] usuaebusiness.org *Report cover, from L to R: Johns Hopkins University President Ronald J. Daniels; Philanthropist, Johns Hopkins Alumnus, and Former New York City Mayor Michael R. Bloomberg; U.A.E. Ambassador Yousef Al Otaiba; Dean of Johns Hopkins University Medical Faculty and CEO of Johns Hopkins Medicine Paul Rothman (photo credit Nick Khazal, U.A.E. Embassy) 1 INTRODUCTION 2018 was another landmark year for the U.A.E.’s healthcare sector and its partnerships with leading U.S. institutions. In February 2018, the U.A.E. Embassy in Washington, D.C. and Johns Hopkins Medicine announced a new institute for stroke research and clinical care. The Sheikh Khalifa Stroke Institute, established through a $50 million gift from the U.A.E., will feature facilities in Baltimore and Abu Dhabi.1 The Institute will enable Johns Hopkins scientists to collaborate with their Emirati colleagues, training a workforce of biomedical researchers in the U.A.E.2 Furthermore, in April 2018, the U.A.E. Ambassador to the U.S., His Excellency Yousef Al Otaiba, signed memoranda of understanding (MoUs) with leaders from several top American hospitals on behalf of U.A.E.
    [Show full text]
  • Major European Markets
    Gen 27-02-15 Pg.1_Gen 18/11/05 Pg. 1 25/02/2015 18:33 Page 1 27 February2015 COMPANY NEWS 2 RivalstoRemicade reach Cipla gains ground in 2 North Africa via JVs Actavis intends to adopt Allergan name 3 Te va plans to set up abiologicals facility 4 major European markets Wockhardt resolves faults at US factory 5 Sawai sees turnoverrise 6 faster than profit ivals to the Remicade (infliximab) monoclonal antibody marketed by Janssen and Aurobindo venturetotarget PCV vaccines 7 RMerck arenow available throughout Europe after Celltrion and Hospira seized on Growth in US helps Zydus to advance 8 expiries of paediatric extensions to supplementary protection certificates (SPCs) during Lannett turns gaze to Western Europe 9 February to enter the market (see pages 24 and 28). Russia and Ukraine hit Richter’sresults 10 On 25 February,Celltrion announced launches of its Remsima biosimilar through partners such as Kern Pharma and Mundipharma (see page 26) in Austria, Belgium, Denmark, France, Protopic rival peps Perrigo’sturnover 11 Germanyand Greece, as well as in Italy,Luxembourg, the Netherlands, Spain, Sweden and the To wa cuts its costs to improvemargins 12 UK. The treatment for autoimmune diseases wasnow available in 31 countries, the firm noted. Siegfried sorts out FDAHameln letter 13 Hospira has launched its Inflectra (infliximab) biosimilar monoclonal antibody in Glenmark growsits sales as profits slide 14 several European markets, includingAustria, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain and Sweden. “Inflectra is nowavailable in 24 European MARKET NEWS 15 countries,”noted the injectables specialist, which already markets infliximab in Central and Eastern Europe, as well as in some smaller Western European markets.
    [Show full text]
  • Mediworld 12Th November-December 2018.Cdr
    Vol. 02, Issue 06, No. 12, Nov-Dec 2018 Health Overview The Kingdom of Saudi Arabia FEATURES NEWS & UPDATES HEALTH DESTINATION A 'Game Changer' Julphar announces Maintaining the Nordic India's National Health entry into oncology welfare model with universal Protection Scheme market healthcare www.mediworldme.com Middle East Air Cargo & Logistics Conference Connecting Middle East to the World and World to the Middle East January 29-30, 2019 | Dubai South HQ | Dubai, UAE Middle East Air Cargo & Logistics 2019 will bring together airlines, airports, forwarders, shippers, brokers, logistics & supply chain companies, and aviation service providers to gain market intelligence and excellent networking. Air cargo and logistics executives from the Middle East and globally will join for this unique conference, and discuss the future trends in air freight logistics. The UAE government has heavily invested on infrastructure and technology to facilitate seamless cargo transportation and supply chains. Learn about your business opportunities in this exciting region! Program Highlights The big picture on Air Cargo & the global Expo 2020 -assessment of supply chain procurement of opportunities Will Middle East keep its position as Building world competitive leading cargo gateway? airports/cargo hubs Innovation in Logistics & Supply Chain E-commerce -redefining industry relationship Artificial Intelligence in logistics - what to expect? Humanitarian logistics Shipper’s view The future of the air cargo industry Host Sponsor Endorsed by Organized by NATIONAL
    [Show full text]
  • Health-Sector-In-Dubai.Pdf
    اﻟﻘﻧﺻﻠﯾﺔ اﻟﻣﺻرﯾﺔ ﻟﺟﻣﮭورﯾﺔ ﻣﺻر اﻟﻌرﺑﯾﺔ ﻣﻛﺗب اﻟﺗﻣﺛﯾل اﻟﺗﺟﺎري دﺑﻰ واﻻﻣﺎرات اﻟﺷﻣﺎﻟﯾﺔ اﻟﺷرﻛﺎت اﻻﻣﺎرﺗﯾﺔ اﻟﻌﺎﻣﻠﺔ ﻓﻲ ﻣﺟﺎل اﻟﺻﺣﺔ * أھم اﻟﻣﺳﺗﺷﻔﯾﺎت * ﻣﺳﺗوردي اﻷﺟﮭزة واﻟﻣﺳﺗﻠزﻣﺎت اﻟطﺑﯾﺔ * ﻣﺳﺗوردي اﻷدوﯾﺔ واﻟﻣﺳﺗﺣﺿرات اﻟدواﺋﯾﺔ إﻋداد إدوارد ﯾوﻧﺎن أﻛﺗوﺑر 2017 Main Hospitals in UAE NO. Hospital Name Website Email Phone Number 1 Saudi German Hospital Dubai www.sghdubai.ae [email protected] 0097143890000 2 Al Zahra Hospital Dubai www.azhd.ae [email protected] 0097143786666 3 American Hospital Dubai www.ahdubai.com [email protected] 0097143367777 4 Al Garhoud Hospital Dubai www.gph.ae [email protected] 0097144545000 American British Surgical & Medical 5 www.absamc.com [email protected] 0097142975544 Centre [email protected] 6 Armada Hospital www.armadahospital.com 0097143990022 [email protected] [email protected] 7 Canadian Specialist Hospital www.csh.ae 0097147072222 [email protected] 0097143454000 8 Belhoul European Hospital www.belhouleuropean.com [email protected] 0097143457500 0097144400500 9 Aster Hospital asterhospital.com [email protected] 0097144546001 11 City Hospital Dubai www.mediclinic.ae [email protected] 0097144359999 12 Dubai Hospital web.dohms.gov.ae/dh/ [email protected] 0097142195000 13 Dubai London Specialty Hospital dubailondonclinic.com [email protected] 0097143782999 14 Iranian Hospital Dubai www.ihd.ae [email protected] 0097143440250 15 Lifeline Hospital www.lifeline.ae/lifeline-hospital [email protected] 80046774825 16 Zulekha Hospital zulekhahospitals.com [email protected] 0097142678866 0097142811000 17 Al Jalila Children’s Specialty Hospital www.aljalilahospital.com [email protected] 8008002524 18 Hatta Hospital www.dha.gov.ae [email protected] 0097148147000 0097142191000 19 Rashid Hospital www.dha.gov.ae [email protected] 0097142192000 0097143371111 20 Cedars International Hospital www.cedars-jaih.com [email protected] 0097148814000 Main Importers of Pharmaceutical Products in UAE Products NO.
    [Show full text]
  • Alvarez & Marsal Middle East
    Contents About this Report 3 Executive Summary 4 About Us 5 Our Organizational Profile 5 Our Mission, Vision and Values 8 Responding to COVID-19 10 Our Approach to Sustainability 11 What Sustainability Means to Us 11 Contribution to National and Regional Development 11 Our 2020 Performance 12 Sustainability Governance 12 Stakeholder Engagement and Materiality 13 Our Environmental Performance 16 Managing Our Resources 17 Our Social Performance 23 Our Commitment to our People 24 Our Commitment to our Community and Customers 31 Our Governance Performance 40 Risk Management 41 Our Corporate Governance 41 Compliance with Regulations 45 GRI Index 47 www.julphar.net 2 About this Report This report represents a new chapter for Julphar. We commit to enhancing stakeholder awareness of our priority Environmental, Social, and Governance (ESG) topics and disclosing how our performance on non-financial metrics contributes to long-term value creation and a sustainable, responsible and customer-centric business model. This report has been prepared following the Global Reporting Initiative (GRI) Standards "Core" option, with further references to the Abu Dhabi Stock Exchanges 31 Key Performance Indicators. Additionally, the report outlines our commitment towards the 17 Sustainable Development Goals (SDGs) of the United Nations 2030 Agenda for Sustainable Development, with relevant SDGs identified in each of our priority areas. We are now committed to reporting on sustainability measures annually, alongside our Governance Report, which provides a thorough overview of our financial, governance, and risk performance. Accordingly, we have structured the report into three main themes, Environmental, Social, and Governance, to cover our most material ESG issues.
    [Show full text]
  • The Pharma 1000 Top Global Pharmaceutical Company Report
    The Pharma 1000 Top Global Pharmaceutical Company Report September 2020 © 2020. All rights reserved. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. In Europe such services are offered through Torreya Partners (Europe) LLP, which is authorized and regulated by the UK Financial Conduct Authority. 1 Table of Contents The Evolving Global Pharmaceutical Sector 5 The Biotechnology Sector 16 The Branded Pharma Sector 24 The Generic Drug Sector 34 Financial Players in Pharma: Private Equity and Royalty Firms 38 Top Players by Country and Segment 44 The Pharma 1000 List 55 About Torreya and Acknowledgements 96 2 Torreya’s Pharma 1000 Report . Torreya is a globally active investment bank focused on the pharmaceutical sector. We began to track assets, people and companies in the industry with our own database in 2012. In “The Pharma 1000” report, we leverage our database to identify the top 1000 companies by value today. This presentation provides a summary of the key findings of the report. We hope to give you a greater sense of the global scale of the pharmaceutical industry and its extraordinary growth. We also wish to recognize the companies that appear on the Pharma 1000 list for the accomplishment of becoming a top company in one of the world’s most important and challenging Download the Full Report industries. 3 Torreya Pharma 1000 Study Approach . We identified approximately 30,000 pharmaceutical companies in 2012. Our team studied these companies and pulled out the active operating companies in ethical pharmaceuticals which had a tangible basis for valuation.
    [Show full text]
  • By UNAIDS and the China Chamber Of
    21 COUNTRY PROFILES An Introduction to Local Pharmaceutical Production Opportunities in Africa TABLE OF CONTENTS: Foreword from UNAIDS 01 02 Foreword from CCCMHPIE Acknowledgements 03 Introduction to Country Profiles 04 Country Profile 1: ALGERIA 11 Country Profile 2: ANGOLA 14 Country Profile 3: CÔTE D’IVOIRE 17 Country Profile 4: EGYPT 20 Country Profile 5: ETHIOPIA 23 Country Profile 6: GABON 26 Country Profile 7: GHANA 29 Country Profile 8: KENYA 32 Country Profile 9: MADAGASCAR 35 Country Profile 10: MALAWI 38 Country Profile 11: MALI 41 Country Profile 12: MAURITIOUS 44 Country Profile 13: MOZAMBIQUE 47 Country Profile 14: NIGERIA 50 Country Profile 15: RWANDA 53 Country Profile 16: SENEGAL 56 Country Profile 17: SOUTH AFRICA 59 Country Profile 18: TANZANIA 62 Country Profile 19: UGANDA 65 Country Profile 20: ZAMBIA 68 Country Profile 21: ZIMBABWE 71 Bibliography 74 FOREWORD FROM UNAIDS A healthy population is essential for prosperity. also strongly believe that local production of This is a now accepted principle of development, medicines and other health products in Africa reflected in the UN Sustainable Development is an attractive proposition - it is estimated Goals agreed in 2015, and in particular SDG3 that the African pharmaceutical sector holds for good health and wellbeing. The principle is a US $45 billion market opportunity by 2020. also reflected in the African continent’s vision Local pharmaceutical manufacturing in African for itself – Agenda 2063, also published in 2015 countries presents an opportunity to save lives by the African Union, and in collective actions while creating jobs and improving the local since 2015 by African countries to strengthen economy.
    [Show full text]
  • Other Service Providers Within UAE for Daman's Health Insurance Plans
    Other Service Providers within UAE for Daman ’s Health Insurance Plans (InsertDaman TitleProvider Here) Net work – Other Service Providers within UAE for Daman’s Health Insurance Plans This document lists out Health Service Providers like Polyclinics, Diagnostic Centers, Primary Health Care Centers, etc., available in Daman’s Network, offering inpatient and/or outpatient services as covered in your policy, for Daman’s Health Insurance Plan (including Essential Benefits Plan, Classic, Care, Secure, Core, Select, Enhanced, Premier and CoGenio Plan) members. Daman also covers its members for other inpatient and outpatient services in its network of Health Service Providers (including Hospitals, Pharmacies and Dental service providers) For more details on such health service providers, please refer to the Provider Network Directory of your plan on our website www.damanhealth.ae or call us on the toll free number mentioned on your Daman Card. Edition: October 01, 2015 Exclusive 1 covers CoGenio, Premier, Premier DNE, Enhanced Platinum Plus, Select Platinum Plus, Enhanced Platinum, Select Platinum, Care Platinum DNE, Enhanced Gold Plus, Select Gold Plus, Enhanced Gold, Select Gold, Care Gold DNE Plans Comprehensive 2 covers Enhanced Silver Plus, Select Silver Plus, Enhanced Silver, Select Silver Plans Comprehensive 3 covers Enhanced Bronze, Select Bronze Plans Standard 2 covers Care Silver DNE Plan Standard 3 covers Care Bronze DNE Plan Essential 5 covers Core Silver, Secure Silver, Core Silver R, Secure Silver R, Core Bronze, Secure
    [Show full text]